ArticleBlood advances2025
Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma.PharmacoEconomics · 2026Article
- Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis.Cancer research communications · 2026Article
- Reassessing IgRT in CLL: evidence still unconvincing.Blood advances · 2026Article
- Vaccination should not be forgotten in patients receiving immunoglobulin replacement therapy.Blood advances · 2026Article
- Too soon to reject immunoglobulin replacement in CLL.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPatients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.